详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Hematopoietic stem cell transplantation activity in China 2020-2021 during the SARS-CoV-2 pandemic: a report from the Chinese Blood and Marrow Transplantation Registry Group

146| 认领 | 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

机构： [1]Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China [2]Hebei Yanda Lu Daopei Hospital & Beijing Ludaopei Hospital, Langfang, Hebei & Beijing, China [3]The First Affiliated Hospital of Soochow University, National Clinical Research Center for Hematologic Disease, Soochow, China [4]Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, China [5]Chinese PLA General Hospital, Beijing, China [6]The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China [7]The First Affiliated Hospital of University of Science and Technology of China, Hefei, China [8]Fujian Medical University Union Hospital,Fujian Provincial Key Laboratory of Hematology, Fujian Institute of Hematology, Fuzhou, China [9]Nanfang Hospital, Guangzhou, China [10]Xinqiao Hospital of Army Medical University, Chongqing, China [11]The First Affiliated Hospital of Guangxi Medical University, Nanning, China [12]Henan Cancer Hospital, the Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China [13]Shanghai General Hospital, Shanghai, China [14]Shenzhen Children’s Hospital, Shenzhen, China [15]Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China [16]Shanghai Children’s Medical Center, Shanghai, China [17]Union Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China [18]West China Hospital, Sichuan University, Chengdu, China

出处：

DOI：

ISSN：

摘要：

Between 2020 and 2021, 31,525 hematopoietic stem cell transplantations (HSCTs) were reported to the Chinese Blood and Marrow Transplantation Registry Group (CBMTRG) throughout mainland China. In this report, we describe the activity and current trends for HSCT in China during the SARS-CoV-2 pandemic. In 2020, a total of 13,415 cases of HSCT were reported from 166 transplant teams, and 75% (10,042 cases) were allogeneic HSCTs. In 2021, a total of 18,110 cases of HSCT were reported from 174 transplant teams, and 70% (12,744 cases) were allogeneic HSCTs. Haploidentical donor (HID) transplantation accounted for 63% (7977 cases) of allogeneic HSCTs in 2021. The most common indications for allogeneic HSCT for malignant disease were acute myeloid leukemia (AML) (37%) and acute lymphoblastic leukemia (ALL) (23%), and the largest proportion of nonmalignant disease comprised aplastic anemia (AA) (13%). The PB stem cell source accounted for 41% of HIDs and 75% of MSDs. The BuCy-based regimen (57%) was the most popular conditioning regimen for allogeneic HSCT, followed by the BuFlu-based regimen (28%) and TBI-based regimen (11%). This survey provides comprehensive information about the current activities and might benefit clinical physicians' decision planning for HSCT.Copyright © 2022. Published by Elsevier Inc.

基金：

基金编号： 2017YFA0104500 81930004

语种：

被引次数：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2023]版：

大类 | 3 区医学

小类 | 3 区血液学 3 区免疫学 3 区移植

最新[2023]版：

大类 | 3 区医学

小类 | 3 区血液学 3 区免疫学 3 区移植

JCR分区：

出版当年[2023]版：

Q1 TRANSPLANTATION Q2 HEMATOLOGY Q2 IMMUNOLOGY

最新[2023]版：

Q1 TRANSPLANTATION Q2 HEMATOLOGY Q2 IMMUNOLOGY

影响因子： 3.6 最新[2023版] 3.6 最新五年平均 3.6 出版当年[2023版] 3.6 出版当年五年平均 3.2 出版前一年[2022版]

第一作者：

第一作者机构： [1]Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China

通讯作者：

推荐引用方式(GB/T 7714)：

APA：

MLA：